m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02251)
Name
3,7,3',4'-TETRAHYDROXYFLAVONE
Synonyms
Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H10O6
InChI
1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H
InChIKey
XHEFDIBZLJXQHF-UHFFFAOYSA-N
PubChem CID
5281614
TTD Drug ID
D0MF5Y
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 6 (CDK6)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 6 (CDK6) is a therapeutic target for 3,7,3',4'-TETRAHYDROXYFLAVONE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,7,3',4'-TETRAHYDROXYFLAVONE through regulating the expression of Cyclin-dependent kinase 6 (CDK6). [1], [2]
Fatty acid synthase (FASN)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Fatty acid synthase (FASN) is a therapeutic target for 3,7,3',4'-TETRAHYDROXYFLAVONE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,7,3',4'-TETRAHYDROXYFLAVONE through regulating the expression of Fatty acid synthase (FASN). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Fatty acid synthase (FASN) is a therapeutic target for 3,7,3',4'-TETRAHYDROXYFLAVONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,7,3',4'-TETRAHYDROXYFLAVONE through regulating the expression of Fatty acid synthase (FASN). [4], [5]
References
Ref 1 FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner. Cell Death Discov. 2021 Nov 1;7(1):329. doi: 10.1038/s41420-021-00724-5.
Ref 2 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. doi: 10.1016/s0165-6147(02)02071-0.
Ref 3 Fat mass and obesity-associated protein regulates lipogenesis via m(6) A modification in fatty acid synthase mRNA. Cell Biol Int. 2021 Feb;45(2):334-344. doi: 10.1002/cbin.11490. Epub 2020 Nov 8.
Ref 4 Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. doi: 10.1021/jm0600545.
Ref 5 METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019 Oct 8;518(1):120-126. doi: 10.1016/j.bbrc.2019.08.018. Epub 2019 Aug 10.